DoW Spinal Cord Injury, Translational Research Award | HT942526SCIRPTRA

FY26 SCIRP Translational Research Award (TRA) - Frequently Asked Questions

1) What is the FY26 Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA)?

The FY26 SCIRP Translational Research Award (TRA) is a discretionary U.S. Department of the Army (USAMRAA) grant opportunity that supports translational spinal cord injury (SCI) research intended to speed progress from promising research ideas to real-world clinical applications.

2) Who is offering this funding opportunity?

The opportunity is offered by the U.S. Department of the Army through USAMRAA (U.S. Army Medical Research Acquisition Activity).

3) What type of funding instrument is this?

This opportunity uses a grant mechanism (Funding Instrument Type: Grant).

4) What is the main focus or emphasis of the Translational Research Award?

The emphasis is on research that moves beyond basic discovery and actively supports development, validation, and practical advancement of approaches that can plausibly reach patients, clinicians, and care settings.

5) Is basic discovery research the main goal of this award?

No. The described emphasis is on work that goes beyond basic discovery, with the goal of supporting clinically relevant translation toward real-world application.

6) What does "translational" mean in the context of this award?

Based on the description provided, "translational" refers to research that helps move promising SCI ideas toward clinical application by supporting development, validation, and practical advancement so the results can realistically reach patients and care settings.

7) Is community involvement required for all applications?

Yes. A defining requirement is meaningful involvement of the SCI community in the research process.

8) What is required regarding an SCI community partner?

Every application must include at least one SCI community partner, such as a lived-experience consultant or a representative from a community-based organization.

9) What role is the SCI community partner expected to play?

The SCI community partner is expected to provide ongoing advice and consultation throughout both the planning and execution of the project, helping ensure the work is grounded in patient and community priorities, feasibility, and impact.

10) Can the SCI community partner be a lived-experience consultant?

Yes. The opportunity explicitly lists a lived-experience consultant as an example of an SCI community partner.

11) Can the SCI community partner be from a community-based organization?

Yes. A representative from a community-based organization is explicitly listed as an example of an SCI community partner.

12) Is there an option designed specifically for early-career investigators?

Yes. The opportunity includes an Early-Career Partnership Option intended to support collaborative leadership and help develop newer investigators.

13) What is the Early-Career Partnership Option?

It is an option under which a project may name two principal investigators (PIs), as long as at least one of the PIs qualifies as an early-career investigator.

14) How many principal investigators (PIs) can be named under the Early-Career Partnership Option?

Two PIs may be named under this option.

15) What is the key eligibility condition for the PIs under the Early-Career Partnership Option?

At least one of the two PIs must qualify as an early-career investigator.

16) How does the submission process work under the Early-Career Partnership Option?

The submission is coordinated but split. At the pre-application stage, only the initiating PI submits the pre-application. At the full application stage, both PIs must submit applications.

17) Who submits the pre-application under the Early-Career Partnership Option?

Only the initiating PI submits the pre-application.

18) What happens at the full application stage under the Early-Career Partnership Option?

Both PIs must submit applications. The partnering PI submits an abbreviated application focused on their distinct part of the overall research plan.

19) What is included in the partnering PI's full application submission?

The partnering PI submits an abbreviated application focused on their distinct part of the overall research plan.

20) If funded, how are awards issued under the Early-Career Partnership Option?

If selected for funding, each PI is issued a separate award to their respective recipient organization(s).

21) Are the paired submissions linked for review/administrative purposes?

Yes. Applicants are told to note the linkage between the paired submissions.

22) What happens if one of the paired applications is rejected or administratively withdrawn?

If either the initiating or partnering application is rejected or administratively withdrawn, the entire set of associated applications for that joint project may also be withdrawn.

23) What is the opportunity number for this funding announcement?

The opportunity number is HT942526SCIRPTRA.

24) What is the closing date listed for this opportunity?

The original closing date is November 12, 2026.

25) How many awards does the program anticipate making?

The program anticipates making about four awards.

26) What is the award ceiling (maximum funding amount) for this opportunity?

An award ceiling is referenced, but the specific maximum amount is not provided in the information excerpt.

27) What is the CFDA number and program category for this opportunity?

The CFDA number is 12.420, and the opportunity is categorized under science and technology/research and development.

28) Who is eligible to apply?

Eligibility is listed as unrestricted, meaning a broad range of applicant organizations may apply.

29) What is the overall goal of the award in terms of impact?

The stated goal is to speed the path from promising research ideas to real-world clinical applications in spinal cord injury, with research grounded in patient and community priorities and with a plausible route to clinical use.